Background: interferon-α is able to induce a sustained inhibition of hepatitis B virus replication in about 30-40% of patients with chronic hepatitis B. There is evidence that non-steroidal antiinflammatory drugs can enhance the synthesis of antiviral proteins induced by interferon-α. Aim: to evaluate the efficacy and tolerability of combined therapy with interferon-α plus indomethacin in HBeAg and HBV-DNA positive patients affected by chronic active hepatitis non-responders to a previous interferon-a treatment. Methods: after six months of retreatment with interferon-α (6 MU thrice weekly) six patients were enrolled, without stopping the therapy, to receive interferon-α (with the same schedule) plus indomethacin (25 mg orally twice daily) for an additional six month course. Results: at the end of treatment and after six months of follow-up alanine transaminase normalization was seen in three (50%) and four (66.7%) patients, HBV-DNA loss in one (17%) and three (50%), HBeAg/HBeAb serum conversion in one (17%) and two (33%), respectively. The combined therapy was well tolerated and no indomethacin side-effects were observed. The treatment was stopped in one patient after 4 months because of a remarkable increase of alanine transaminase levels, and in another after five months because of hyperthyroidism occurrence. Conclusions: the results of this study, even if obtained in a small number of patients, are encouraging and suggest a randomized controlled trial to be confirmed.

Interferon-α plus indomethacin combined therapy in HBeAg positive chronic hepatitis B non-responder to a previous IFNα course: Results of a pilot study / Andreone, P.; Cursaro, C.; Gramenzi, A.; Miniero, R.; Bernardi, M.; Gasbarrini, G.. - In: INTERNATIONAL HEPATOLOGY COMMUNICATIONS. - ISSN 0928-4346. - 5:3(1996), pp. 151-159. [10.1016/0928-4346(96)00286-1]

Interferon-α plus indomethacin combined therapy in HBeAg positive chronic hepatitis B non-responder to a previous IFNα course: Results of a pilot study

Andreone P.;Cursaro C.;
1996

Abstract

Background: interferon-α is able to induce a sustained inhibition of hepatitis B virus replication in about 30-40% of patients with chronic hepatitis B. There is evidence that non-steroidal antiinflammatory drugs can enhance the synthesis of antiviral proteins induced by interferon-α. Aim: to evaluate the efficacy and tolerability of combined therapy with interferon-α plus indomethacin in HBeAg and HBV-DNA positive patients affected by chronic active hepatitis non-responders to a previous interferon-a treatment. Methods: after six months of retreatment with interferon-α (6 MU thrice weekly) six patients were enrolled, without stopping the therapy, to receive interferon-α (with the same schedule) plus indomethacin (25 mg orally twice daily) for an additional six month course. Results: at the end of treatment and after six months of follow-up alanine transaminase normalization was seen in three (50%) and four (66.7%) patients, HBV-DNA loss in one (17%) and three (50%), HBeAg/HBeAb serum conversion in one (17%) and two (33%), respectively. The combined therapy was well tolerated and no indomethacin side-effects were observed. The treatment was stopped in one patient after 4 months because of a remarkable increase of alanine transaminase levels, and in another after five months because of hyperthyroidism occurrence. Conclusions: the results of this study, even if obtained in a small number of patients, are encouraging and suggest a randomized controlled trial to be confirmed.
1996
5
3
151
159
Interferon-α plus indomethacin combined therapy in HBeAg positive chronic hepatitis B non-responder to a previous IFNα course: Results of a pilot study / Andreone, P.; Cursaro, C.; Gramenzi, A.; Miniero, R.; Bernardi, M.; Gasbarrini, G.. - In: INTERNATIONAL HEPATOLOGY COMMUNICATIONS. - ISSN 0928-4346. - 5:3(1996), pp. 151-159. [10.1016/0928-4346(96)00286-1]
Andreone, P.; Cursaro, C.; Gramenzi, A.; Miniero, R.; Bernardi, M.; Gasbarrini, G.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1288058
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact